» Articles » PMID: 9517939

Oxfendazole Treatment for Cystic Hydatid Disease in Naturally Infected Animals

Overview
Specialty Pharmacology
Date 1998 Mar 28
PMID 9517939
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Few chemotherapeutic agents are available for the medical management of hydatid disease caused by the parasite Echinococcus granulosus. In order to test the potential of oxfendazole for the treatment of infection with this parasite, nine infected goats and four sheep were given oxfendazole twice weekly at a dose of 30 mg/kg of body weight for 4 weeks and monitored by ultrasound for an additional 4 weeks. Efficacy was finally evaluated by postmortem examination, including determination of protoscolex viability and cyst wall histology. In treated animals, protoscolices were dead or absent in 97% of cysts from oxfendazole-treated animals compared to 28% of cysts from untreated control animals. On postmortem examination, 53% of cysts from treated animals were found to be grossly degenerate. A sample of those cysts that appeared potentially viable all demonstrated evidence of severe damage to the cyst wall. By light microscopy, cysts showed severe disorganization of the adventitial layer with invasion of inflammatory cells and in some cases frank necrosis with no apparent adventitial layer. The follow-up period for assessment of the drug's ability to cause complete degeneration and resorption of cysts was relatively short. This study, however, indicates that oxfendazole is at least as effective as and is easier to administer than albendazole for the treatment of hydatid disease.

Citing Articles

Ruta graveolens, Peganum harmala, and Citrullus colocynthis methanolic extracts have in vitro protoscolocidal effects and act against bacteria isolated from echinococcal hydatid cyst fluid.

Al Qaisi Y, Khleifat K, Oran S, Al Tarawneh A, Qaralleh H, Al-Qaisi T Arch Microbiol. 2022; 204(4):228.

PMID: 35353289 DOI: 10.1007/s00203-022-02844-7.


Response patterns in adventitial layer of Echinococcus granulosus sensu stricto cysts from naturally infected cattle and sheep.

Hidalgo C, Stoore C, Baquedano M, Pereira I, Franco C, Hernandez M Vet Res. 2021; 52(1):66.

PMID: 33962666 PMC: 8105927. DOI: 10.1186/s13567-021-00936-8.


The Burden of Cystic Echinococcosis in Kenya: A Review Article.

Kia E, Ouma F, Mulambalah C, Okoth P Iran J Parasitol. 2020; 14(4):502-509.

PMID: 32099553 PMC: 7028223.


Oxfendazole: a promising agent for the treatment and control of helminth infections in humans.

Gonzalez A, Codd E, Horton J, Garcia H, Gilman R Expert Rev Anti Infect Ther. 2018; 17(1):51-56.

PMID: 30501436 PMC: 6376865. DOI: 10.1080/14787210.2018.1555241.


Progress in the pharmacological treatment of human cystic and alveolar echinococcosis: Compounds and therapeutic targets.

Siles-Lucas M, Casulli A, Cirilli R, Carmena D PLoS Negl Trop Dis. 2018; 12(4):e0006422.

PMID: 29677189 PMC: 5931691. DOI: 10.1371/journal.pntd.0006422.


References
1.
Arthaud J . Cause of death in 339 Alaskan natives as determined by autopsy. Arch Pathol. 1970; 90(5):433-8. View

2.
Maxson A, Wachira T, Zeyhle E, Fine A, Mwangi T, Smith G . The use of ultrasound to study the prevalence of hydatid cysts in the right lung and liver of sheep and goats in Turkana, Kenya. Int J Parasitol. 1996; 26(11):1335-8. DOI: 10.1016/s0020-7519(96)00124-5. View

3.
Gemmell M, Johnstone P, Oudemans G . The effect of oxfendazole on Echinococcus granulosus and Taenia hydatigena infections in dogs. Res Vet Sci. 1979; 26(3):389-90. View

4.
Marriner S, Bogan J . Pharmacokinetics of albendazole in sheep. Am J Vet Res. 1980; 41(7):1126-9. View

5.
SMYTH J, Barrett N . Procedures for testing the viability of human hydatid cysts following surgical removal, especially after chemotherapy. Trans R Soc Trop Med Hyg. 1980; 74(5):649-52. DOI: 10.1016/0035-9203(80)90157-1. View